Atossa Therapeutics receives FDA 'Study May Proceed' letter for (Z)-Endoxifen metastatic breast cancer trial

ATOSSA THERAPEUTICS, INC.

FDA issued 'Study May Proceed' letter for Atossa's IND for (Z)-Endoxifen in metastatic ER+/HER2- breast cancer.
Trial will evaluate (Z)-Endoxifen in tumors resistant to other endocrine therapies; targets PKCβ1 pathway.
CEO Dr. Steven Quay calls this an important regulatory milestone to expand (Z)-Endoxifen's potential use.
(Z)-Endoxifen is a potent SERM/D with distinct pharmacology from tamoxifen; not yet approved for any indication.
Program backed by growing global IP portfolio including issued U.S. patents and pending applications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.